Search | Clinical Trials Finder

Conditions: Human Papillomavirus
Interventions: Gardasil; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 27 Years to 45 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy, Cancer Vaccine
Interventions: Docetaxel, Cisplatin, PRGN-2009; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 1,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 35
States / cities: Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more

Conditions: Head and Neck Cancer, Head and Neck Neoplasms
Interventions: M7824, N803, TriAd vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HPV Vaccine
Interventions: Intervention Arm; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 10 Years to 12 Years
Enrollment: 2,232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HPV Immunization Status
Interventions: Multimodal Vaccine Program; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years and older
Enrollment: 93,582 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Human Papilloma Virus
Interventions: Health Education Session; Behavioral
Lead sponsor: MEE Productions, Inc.; Other
Eligibility: Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Human Papilloma Virus-Related Cervical Carcinoma
Interventions: HPV brochure, recall, reminders, General Adolescent Vaccine Brochure; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 11 Years to 18 Years · Female only
Enrollment: 831 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Primary Prevention
Interventions: Boot Camp Translation, Control; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years to 26 Years
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Human Papillomavirus, Uterine Cervical Neoplasms
Interventions: Educational materials; Behavioral
Lead sponsor: Meharry Medical College; Other
Eligibility: 9 Years and older
Enrollment: 806 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ewing's Sarcoma, Rhabdomyosarcoma
Interventions: EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine; Other · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 27 Years to 69 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Seattle, Washington

Conditions: HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07; Drug
Lead sponsor: Theravectys S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma

Conditions: HPV
Interventions: brief informational intervention to promote HPV vaccine acceptance; Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: 11 Years and older
Enrollment: 614 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Recurrent Respiratory Papillomatosis
Interventions: Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cervical Cancer
Interventions: BNI-brief Negotiated Interview; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 11 Years to 15 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
Interventions: DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging, Biopsy; Biological · Procedure
Lead sponsor: Michael K. Gibson; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Nashville, Tennessee

Conditions: HPV-Associated Cancers
Interventions: Ad-E6E7, MG1-E6E7, Atezolizumab; Biological
Lead sponsor: Turnstone Biologics, Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Miami, Florida • Billings, Montana • New York, New York + 2 more

Conditions: Chronic Kidney Diseases, Kidney Transplant
Interventions: Human Papilloma Virus vaccine (GARDASIL 9); Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cervical Cancer, Genital Warts
Interventions: Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late; Biological
Lead sponsor: Duke University; Other
Eligibility: 9 Years to 18 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review; Biological · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 9 Years to 26 Years
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more

Conditions: Adenocarcinoma of the Prostate
Interventions: Cyclophosphamide, DRibble Vaccine, HPV Vaccinations, Imiquimod; Drug · Biological
Lead sponsor: UbiVac; Industry
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Increase in Use of Immunization Registry, Increase in HPV Vaccination Rate
Interventions: Reminder Recall Report, Audit-Feedback/Immunization Forecasting Reports; Other
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Study of Gardasil in Mid-Adult Males (MAM)

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

HPV Ends Here: Increasing Uptake of the HPV Vaccine

Strengthening Physician Communication About HPV Vaccines

Promoting Human Papillomavirus (HPV) Vaccination Through African American Beauty Salons

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

An Intervention Promoting HPV Vaccination in Safety-net Clinics

Engaging Practices and Communities in the Development of Interventions to Promote HPV Vaccine Uptake

An HPV Vaccine Provider Intervention in Safety Net Clinics

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers

Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

An Intervention Study To Improve Human PapillomaVirus ( HPV) Immunization in Haitian and African American Girls

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

Immunogenicity of HPV Vaccine in Transplant Recipients.

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

Optimizing Application And Support Of Immunization Information Systems (OASIS)